BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics
BCRX Stock Summary
- Biocryst Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.87% of US listed stocks.
- With a price/sales ratio of 115.99, Biocryst Pharmaceuticals Inc has a higher such ratio than 96.65% of stocks in our set.
- As for revenue growth, note that BCRX's revenue has grown -63.53% over the past 12 months; that beats the revenue growth of merely 3.72% of US companies in our set.
- Stocks that are quantitatively similar to BCRX, based on their financial statements, market capitalization, and price volatility, are CRIS, LOGC, XFOR, MRUS, and PTCT.
- Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.biocryst.com.
BCRX Stock Price Chart Interactive Chart >
BCRX Price/Volume Stats
|Current price||$12.05||52-week high||$14.24|
|Prev. close||$11.66||52-week low||$2.75|
|Day high||$12.56||Avg. volume||6,556,769|
|50-day MA||$11.13||Dividend yield||N/A|
|200-day MA||$6.86||Market Cap||2.14B|
BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio
Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.
BCRX Latest News Stream
|Loading, please wait...|
BCRX Latest Social Stream
View Full BCRX Social Stream
Latest BCRX News From Around the Web
Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks initially suffered […]
Following back-to-back losses on the last two days of the week, BioCryst Pharmaceuticals ([[BCRX]] -6.6%) has witnessed an even sharper decline today after regulatory filings indicated that State Street Corporation has slashed its stake in the company.In an SEC Schedule 13G form filed today, State Street has indicated a stake of ~4.1%...
While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...
Shares of BioCryst Pharmaceuticals (BCRX) slumped nearly 17% this week. That's kind of surprising, considering that the company released positive data on its paroxysmal nocturnal hemoglobinuria (a rare blood disease that can cause anemia, blood clots, and impaired bone marrow function) inhibitor, BCX9930. According to the company, the latest data show that the drug "was safe and generally well-tolerated" in clinical trials, and "significantly increased hemoglobin and reduced transfusions in an ongoing dose-ranging trial." And yet, as RBC Capital analyst Brian Abrahams explains, good is not always quite good enough.
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX ) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an inadequate response to C5 inhibitors. The stock was down 7.3% at $12.27 at last check. BioCryst has a market cap of $2.25 billion and a public float of 175 million shares. BioCryst Short Term Chart Analysis: Above, the 5-minute chart on BioCryst shows the stock has built higher lows into a resistance … Full story available on Benzinga.com
BCRX Price Returns
Continue Researching BCRXWant to do more research on Biocryst Pharmaceuticals Inc's stock and its price? Try the links below:
Biocryst Pharmaceuticals Inc (BCRX) Stock Price | Nasdaq
Biocryst Pharmaceuticals Inc (BCRX) Stock Quote, History and News - Yahoo Finance
Biocryst Pharmaceuticals Inc (BCRX) Stock Price and Basic Information | MarketWatch